세계의 갑상선암 진단 시장 : 시장 규모, 점유율 및 동향 분석(암 유형별·기술별·최종 용도별, 지역별), 부문별 예측(2025-2033년)

Thyroid Cancer Diagnostics Market Summary

The global thyroid cancer diagnostics market size was estimated at USD 3.07 billion in 2024 and is projected to reach USD 5.03 billion by 2033, growing at a CAGR of 5.86% from 2025 to 2033. This growth is attributed to the growing incidence of thyroid cancer, growing awareness of early screening programs, and significant technological advancements in diagnostic tools such as imaging modalities and molecular testing.

In addition, increased healthcare spending, favorable reimbursement policies, and a shift toward personalized medicine. Furthermore, the growing aging population, improved healthcare infrastructure, and ongoing research and development efforts further support market expansion, enabling earlier and more accurate detection and management of thyroid cancer.

Thyroid cancer diagnostics encompass a broad range of tests and procedures, including imaging, biopsies, blood tests, and molecular profiling used to detect and characterize thyroid cancer, guiding clinical decisions and personalized treatment. The global market for these diagnostics is expanding rapidly, largely due to the increasing number of thyroid cancer patients. This rise in cases has heightened the demand for early detection and effective screening tools, as healthcare providers prioritize proactive identification to improve outcomes. According to the American Cancer Society, about 44,020 new cases of thyroid cancer are expected to be diagnosed in the U.S. in 2025. Approximately 31,350 cases occur in women and 12,670 in men. Thyroid cancer is notably more common in women and is often diagnosed at a younger age compared to many other cancers.

A significant driver of this market is technological advancement. For instance, in May 2024, GE Healthcare introduced Revolution RT, an advanced radiation therapy computed tomography (CT) solution. This innovative system is designed to enhance imaging accuracy and streamline simulation workflows, supporting a more personalized and seamless oncology care experience. Revolution RT incorporates AI-driven technologies and updated software platforms, enabling clinicians to achieve precise tumor targeting and more efficient care pathways.

In addition, the adoption of telemedicine and digital health platforms has further expanded access to thyroid cancer diagnostics, especially for individuals in remote or underserved areas. Through virtual consultations, patients can receive early screening recommendations and follow-up care, ensuring timely intervention regardless of geographic barriers.

Moreover, the growing prevalence of genetic testing for hereditary risk factors is creating new opportunities in the market. Advanced genomic panels can identify mutations linked to thyroid tumors, aiding in more accurate diagnosis and personalized treatment strategies. Collectively, these factors, including the rising incidence of thyroid cancer, cutting-edge technology like Revolution RT, the shift toward personalized medicine, digital health accessibility, and expanded genetic testing, are driving robust growth in the thyroid cancer diagnostics industry, leading to earlier detection and improved patient care.

Global Thyroid Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global thyroid cancer diagnostics market report based on cancer type, technique, end use, and region.

• Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
• Papillary carcinoma
• Follicular carcinoma
• Others
• Technique Outlook (Revenue, USD Million, 2021 - 2033)
• Blood Test
• Imaging
• Biopsy
• Others
• End Use Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Laboratories
• Cancer Diagnostic Centers
• Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Denmark
  • Norway
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Cancer Type
  • 1.2.2. Technique
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Cancer Type Outlook
  • 2.2.2. Technique Outlook
  • 2.2.3. End Use Outlook
  • 2.2.4. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Thyroid Cancer Diagnostics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Global Thyroid Cancer Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Global Thyroid Cancer Diagnostics Market: Cancer Type Business Analysis

• 4.1. Cancer Type Segment Dashboard
• 4.2. Thyroid Cancer Diagnostics Market: Cancer Type Movement Analysis
• 4.3. Global Thyroid Cancer Diagnostics Market Size & Trend Analysis, By Cancer Type, 2021 to 2033 (USD Million)
• 4.4. Papillary carcinoma
  • 4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
• 4.5. Follicular carcinoma
  • 4.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Thyroid Cancer Diagnostics Market: Technique Business Analysis

• 5.1. Technique Segment Dashboard
• 5.2. Thyroid Cancer Diagnostics Market: Technique Movement Analysis
• 5.3. Global Thyroid Cancer Diagnostics Market Size & Trend Analysis, By Technique, 2021 to 2033 (USD Million)
• 5.4. Blood Test
  • 5.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
• 5.5. Imaging
  • 5.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
• 5.6. Biopsy
  • 5.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Thyroid Cancer Diagnostics Market: End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Thyroid Cancer Diagnostics Market: End Use Movement Analysis
• 6.3. Global Thyroid Cancer Diagnostics Market Size & Trend Analysis, By End Use, 2021 to 2033 (USD Million)
• 6.4. Hospital Laboratories
  • 6.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
• 6.5. Cancer Diagnostic Centers
  • 6.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
• 6.6. Research Institutes
  • 6.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 7. Global Thyroid Cancer Diagnostics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2024 & 2033
• 7.3. Global Thyroid Cancer Diagnostics Market by Regional: Key Takeaways
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key Country Dynamics
    • 7.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.4.1.3. Competitive Scenario
    • 7.4.1.4. U.S. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. Canada Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Mexico Market Estimates and Forecasts 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Germany
    • 7.5.1.1. Key Country Dynamics
    • 7.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.1.3. Competitive Scenario
    • 7.5.1.4. Germany Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. UK Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. France Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. Italy Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.5.3. Competitive Scenario
    • 7.5.5.4. Spain Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Denmark
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.6.3. Competitive Scenario
    • 7.5.6.4. Denmark Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.7.3. Competitive Scenario
    • 7.5.7.4. Sweden Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Norway
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 7.5.8.3. Competitive Scenario
    • 7.5.8.4. Norway Market Estimates and Forecasts 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key Country Dynamics
    • 7.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.1.3. Competitive Scenario
    • 7.6.1.4. Japan Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. China Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. India Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. Australia Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.6.5. Thailand
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Thailand Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 7.6.6.3. Competitive Scenario
    • 7.6.6.4. South Korea Market Estimates and Forecasts 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key Country Dynamics
    • 7.7.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.7.1.3. Competitive Scenario
    • 7.7.1.4. Brazil Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.7.2.3. Competitive Scenario
    • 7.7.2.4. Argentina Market Estimates and Forecasts 2021 to 2033 (USD Million)
• 7.8. Middle East & Africa
  • 7.8.1. South Africa
    • 7.8.1.1. Key Country Dynamics
    • 7.8.1.2. Regulatory Framework/ Reimbursement Structure
    • 7.8.1.3. Competitive Scenario
    • 7.8.1.4. South Africa Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 7.8.2.3. Competitive Scenario
    • 7.8.2.4. South Arabia Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 7.8.3.3. Competitive Scenario
    • 7.8.3.4. UAE Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 7.8.4.3. Competitive Scenario
    • 7.8.4.4. Kuwait Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key Company Heat Map Analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Abbott
    • 8.4.1.1. Company Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. F.Hoffmann-La Roche Ltd.
    • 8.4.2.1. Company Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Thermo Fisher Scientific, Inc.
    • 8.4.3.1. Company Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Siemens Healthcare GmbH
    • 8.4.4.1. Company Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Bio-Rad Laboratories, Inc.
    • 8.4.5.1. Company Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. GE HealthCare
    • 8.4.6.1. Company Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Hologic, Inc.
    • 8.4.7.1. Company Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Koninklijke Philips N.V.
    • 8.4.8.1. Company Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Toshiba Corporation
    • 8.4.9.1. Company Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Agilent Technologies, Inc.
    • 8.4.10.1. Company Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives
  • 8.4.11. Illumina, Inc.
    • 8.4.11.1. Company Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Strategic Initiatives